U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093697) titled 'A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212' on June 23.
Brief Summary: This is a Phase 3, randomized, double-blind, active-controlled, parallel-group, multi-center clinical trial to evaluate the efficacy and safety of DW5121 compared to DW51211 and DW51212 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of DW5121 over DW51211 and DW51212 by comparing the change in total Bronchitis Severity Score (BSS) at Day 4 after administration. Approximately equal numbers of patients were randomized in a 1:1:1 ratio to receive DW5121, DW51211, or DW51212 for 7 ...